Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma

Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases

“…36 Four tumors in our study had mutations in genes with experimental molecular-based therapy for lung carcinoma, namely BRAF, NRAS, PIK3CA, and AKT1. Lung cancer response to the BRAF inhibitors dabrafenib and vemurafenib have been observed in cases reports, 37,38 and it is also under investigation in clinical trials. 12 However, the BRAF mutation observed in our study was a non-V600 mutation, which is inactivating and would not be amenable to BRAF inhibition therapy.…”

Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications

“…Several clinical case reports have been published with partial and complete responses to vemurafenib [Gautschi et al 2012;Peters et al 2013;Robinson et al 2014;Schmid et al 2015] and dabrafenib [Falchook et al 2012;Rudin et al 2013]. However, as expected from the melanoma setting, the responses to single-agent BRAF TKI are short lived due to the development of resistance (typically 5 months for single-agent BRAF TKI treatment) [Gautschi et al 2015].…”

The Impact of Genomic Profiling for Novel Cancer Therapy – Recent Progress in Non-Small Cell Lung Cancer

“…Only a small subset of NSCLC (2%) contains activating BRAF gene mutations (Kris et al, 2014). Due to the low incidence of BRAF mutations in NSCLC, most clinical trials using BRAF inhibitors were done together with other cancer types (Falchook et al, 2012) or as case reports (Rudin et al, 2013; Robinson et al, 2014; Schmid et al, 2015). In some studies, the response was short-lived, with relapse a few months later, and tumor recurrence was associated with other somatic gene mutations such as KRAS .…”